Here's how DOI.ORG makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

DOI . ORG {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Doi.org Make Money
  6. Keywords
  7. Topics
  8. Schema
  9. External Links
  10. Analytics And Tracking
  11. Libraries
  12. Hosting Providers
  13. CDN Services

We began analyzing https://link.springer.com/article/10.1007/s00259-007-0700-2, but it redirected us to https://link.springer.com/article/10.1007/s00259-007-0700-2. The analysis below is for the second page.

Title[redir]:
Amyloid plaque imaging in vivo: current achievement and future prospects | European Journal of Nuclear Medicine and Molecular Imaging
Description:
Introduction Alzheimer’s disease (AD) is a very complex neurodegenerative disorder, the exact cause of which is still not known. The major histopathological features, amyloid plaques and neurofibrillary tangles, already described by Alois Alzheimer, have been the focus in research for decades. Despite a probable whole cascade of events in the brain leading to impairment of cognition, amyloid is still the target for diagnosis and treatment. Discussion The rapid development of molecular imaging techniques now allows imaging of amyloid plaques in vivo in Alzheimer patients by PET amyloid ligands such as Pittsburgh compound B (PIB). Studies so far have revealed high 11C-PIB retention in brain at prodromal stages of AD and a possibility to discriminate AD from other dementia disorders by 11C-PIB. Ongoing studies are focussing to understand the relationship between brain and CSF amyloid processes and cognitive processes. Conclusion In vivo imaging of amyloid will be important for early diagnosis and evaluation of new anti-amyloid therapies in AD.

Matching Content Categories {📚}

  • Education
  • Science
  • Health & Fitness

Content Management System {📝}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🏙️ Massive Traffic: 50M - 100M visitors per month


Based on our best estimate, this website will receive around 80,479,999 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

We're unsure if the website is profiting.

Not all websites focus on profit; some are designed to educate, connect people, or share useful tools. People create websites for numerous reasons. And this could be one such example. Doi.org might be cashing in, but we can't detect the method they're using.

Keywords {🔍}

article, google, scholar, disease, imaging, amyloid, pubmed, alzheimers, cas, brain, pet, alzheimer, dementia, neurology, plaques, patients, neurol, vivo, nordberg, cpib, ann, binding, pittsburgh, cognitive, med, positron, emission, tomography, press, privacy, cookies, content, journal, research, access, nucl, βamyloid, publish, search, molecular, plaque, agneta, impairment, pib, burden, aging, abeta, kepe, klunk, engler,

Topics {✒️}

ec-fp5-project nci-mci month download article/chapter radiofluorinated 6-dialkylamino-2-naphtylethylidene derivatives dialkylamino-6-acylmalonnonitrile substituted naphthalenes 11c-pib pet imaging positron emission tomography beta-amyloid peptide fibrils imaging β-amyloid burden molecular imaging aims molecular imaging techniques article european journal amyloid plaque imaging full article pdf [11c]-pib imaging privacy choices/manage cookies related subjects nucl mol imaging [11c]sb-13 pet β-amyloid imaging swedish research council mol imaging biol alzheimer disease beta-amyloid european economic area amyloid-β peptide pet amyloid ligands alzheimer-related lesions potentional antecendent marker β-amyloid probe article nordberg beta-amyloid plaques a-beta deposition β-amyloid plaques β-amyloid burden imaging brain amyloid anti-amyloid therapies complex neurodegenerative disorder major histopathological features 2-[2-dimethylaminothiazol-5-yl] ethenyl transgenic mouse model parkinsonism relat disord novum 5th floor vivo amyloid imaging dense amyloid plaques conditions privacy policy csf amyloid processes cerebral amyloid angiopathy living mouse model voxel-based analysis frontotemporal lobar degeneration cerebral glucose metabolism

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Amyloid plaque imaging in vivo: current achievement and future prospects
         description:Alzheimer’s disease (AD) is a very complex neurodegenerative disorder, the exact cause of which is still not known. The major histopathological features, amyloid plaques and neurofibrillary tangles, already described by Alois Alzheimer, have been the focus in research for decades. Despite a probable whole cascade of events in the brain leading to impairment of cognition, amyloid is still the target for diagnosis and treatment. The rapid development of molecular imaging techniques now allows imaging of amyloid plaques in vivo in Alzheimer patients by PET amyloid ligands such as Pittsburgh compound B (PIB). Studies so far have revealed high 11C-PIB retention in brain at prodromal stages of AD and a possibility to discriminate AD from other dementia disorders by 11C-PIB. Ongoing studies are focussing to understand the relationship between brain and CSF amyloid processes and cognitive processes. In vivo imaging of amyloid will be important for early diagnosis and evaluation of new anti-amyloid therapies in AD.
         datePublished:2008-01-11T00:00:00Z
         dateModified:2008-01-11T00:00:00Z
         pageStart:46
         pageEnd:50
         sameAs:https://doi.org/10.1007/s00259-007-0700-2
         keywords:
            Positron emission tomography (PET)
            Amyloid
            PIB
            Alzheimer’s disease
            Diagnostic marker
            Nuclear Medicine
            Imaging / Radiology
            Orthopedics
            Cardiology
            Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00259-007-0700-2/MediaObjects/259_2007_700_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00259-007-0700-2/MediaObjects/259_2007_700_Fig2_HTML.gif
         isPartOf:
            name:European Journal of Nuclear Medicine and Molecular Imaging
            issn:
               1619-7089
               1619-7070
            volumeNumber:35
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Agneta Nordberg
               affiliation:
                     name:Karolinska University Hospital Huddinge
                     address:
                        name:Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Division of Alzheimer Neurobiology, Karolinska University Hospital Huddinge, Stockholm, Sweden
                        type:PostalAddress
                     type:Organization
                     name:Karolinska University Hospital Huddinge
                     address:
                        name:Department of Geriatric Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Amyloid plaque imaging in vivo: current achievement and future prospects
      description:Alzheimer’s disease (AD) is a very complex neurodegenerative disorder, the exact cause of which is still not known. The major histopathological features, amyloid plaques and neurofibrillary tangles, already described by Alois Alzheimer, have been the focus in research for decades. Despite a probable whole cascade of events in the brain leading to impairment of cognition, amyloid is still the target for diagnosis and treatment. The rapid development of molecular imaging techniques now allows imaging of amyloid plaques in vivo in Alzheimer patients by PET amyloid ligands such as Pittsburgh compound B (PIB). Studies so far have revealed high 11C-PIB retention in brain at prodromal stages of AD and a possibility to discriminate AD from other dementia disorders by 11C-PIB. Ongoing studies are focussing to understand the relationship between brain and CSF amyloid processes and cognitive processes. In vivo imaging of amyloid will be important for early diagnosis and evaluation of new anti-amyloid therapies in AD.
      datePublished:2008-01-11T00:00:00Z
      dateModified:2008-01-11T00:00:00Z
      pageStart:46
      pageEnd:50
      sameAs:https://doi.org/10.1007/s00259-007-0700-2
      keywords:
         Positron emission tomography (PET)
         Amyloid
         PIB
         Alzheimer’s disease
         Diagnostic marker
         Nuclear Medicine
         Imaging / Radiology
         Orthopedics
         Cardiology
         Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00259-007-0700-2/MediaObjects/259_2007_700_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00259-007-0700-2/MediaObjects/259_2007_700_Fig2_HTML.gif
      isPartOf:
         name:European Journal of Nuclear Medicine and Molecular Imaging
         issn:
            1619-7089
            1619-7070
         volumeNumber:35
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Agneta Nordberg
            affiliation:
                  name:Karolinska University Hospital Huddinge
                  address:
                     name:Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Division of Alzheimer Neurobiology, Karolinska University Hospital Huddinge, Stockholm, Sweden
                     type:PostalAddress
                  type:Organization
                  name:Karolinska University Hospital Huddinge
                  address:
                     name:Department of Geriatric Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:European Journal of Nuclear Medicine and Molecular Imaging
      issn:
         1619-7089
         1619-7070
      volumeNumber:35
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Karolinska University Hospital Huddinge
      address:
         name:Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Division of Alzheimer Neurobiology, Karolinska University Hospital Huddinge, Stockholm, Sweden
         type:PostalAddress
      name:Karolinska University Hospital Huddinge
      address:
         name:Department of Geriatric Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Agneta Nordberg
      affiliation:
            name:Karolinska University Hospital Huddinge
            address:
               name:Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Division of Alzheimer Neurobiology, Karolinska University Hospital Huddinge, Stockholm, Sweden
               type:PostalAddress
            type:Organization
            name:Karolinska University Hospital Huddinge
            address:
               name:Department of Geriatric Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Division of Alzheimer Neurobiology, Karolinska University Hospital Huddinge, Stockholm, Sweden
      name:Department of Geriatric Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(155)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Clipboard.js
  • Prism.js

Emails and Hosting {✉️}

Mail Servers:

  • mx.zoho.eu
  • mx2.zoho.eu
  • mx3.zoho.eu

Name Servers:

  • josh.ns.cloudflare.com
  • zita.ns.cloudflare.com

CDN Services {📦}

  • Crossref

4.34s.